

Note: This is Online Appendix 1 of Bekker L-G, Giovenco D, Baral S, et al. Oral pre-exposure prophylaxis uptake, adherence, and adverse events in among South African men who have sex with men and transgender women. *S Afr J HIV Med.* 2022;23(1), a1405. <https://doi.org/10.4102/sajhivmed.v23i1.1405>

Appendix 1.

TABLE A1-1: Dried blood spot tenofovir-diphosphate adherence data ($N = 45$) among South African men who have sex with men and transgender women in a combination HIV prevention trial, 2015.

	1 month after initiating n (%)	2 months after initiating n (%)	5 months after initiating n (%)	8 months after initiating n (%)	11 months after initiating n (%)
≥ 700 fmol/punch	0 (0%)	7 (16%)	8 (18%)	4 (9%)	3 (7%)
350 to < 700 fmol/punch	13 (29%)	11 (24%)	6 (13%)	6 (13%)	2 (4%)
< 350 fmol/punch	30 (67%)	23 (51%)	26 (58%)	27 (60%)	23 (51%)
Missing	2 (4%)	4 (9%)	5 (11%)	8 (18%)	17 (38%)

Note: Dried blood spots available for Cape Town participants only; tenofovir-diphosphate adherence data does not consider temporary or permanent stops

TABLE 2-A1. Side effects among South African men who have sex with men and transgender women in a combination HIV prevention trial, 2015.

Side effect description	N	Month (N)	Severity (N)
Vomiting	2	M2 (1), M12 (1)	moderate (2)
Hypersensitivity reaction	1	Other (1)	mild (1)
Nausea	6	M2 (2), M3 (1), M12 (1), other (2)	mild (3), moderate (2), missing (1)
Abdominal pain	2	M2 (1), other (1)	mild (1), moderate (1)
Flatulence	1	M2 (1)	mild (1)
Fatigue (other)	2	M2 (2)	mild (1), moderate (1)
Drowsiness (other)	2	M3(1), M5 (1)	mild (2)
Hypersomnia (other)	1	M2 (1)	mild (1)
Tiredness (other)	1	Other (1)	mild (1)
Increased thirst (other)	2	M2 (2)	mild (2)
Dry mouth (other)	1	M3 (1)	mild (1)
Polydipsia (other)	1	M2 (1)	mild (1)
Sweating (other)	1	M3 (1)	mild (1)
Elevated ALT/AST (other)	2	M12 (1), other (1)	severe (2)
Heartburn (other)	4	M2 (1), M6 (1), M9 (1), other (1)	mild (3), moderate (1)
Hyperglycemia symptoms (other)	1	Other (1)	mild (1)
Hypertension (other)	1	M2 (1)	mild (1)
Generalized pruritis (other)	1	M2 (1)	mild (1)
Glycosuria (other)	1	Other (1)	moderate (1)
1+ Glycosuria (other)	2	M9 (2)	mild (2)
3+ Glycosuria (other)	1	M12 (1)	mild (1)
1+ Proteinuria (other)	4	M9 (3), M12 (1)	mild (4)
1+ Protein (other)	1	M12 (1)	mild (1)

TABLE 3-A1. Timeline of PrEP stops among South African men who have sex with men and transgender women in a combination HIV prevention trial who seroconverted (n=5), 2015

PrEP stop: Days after PrEP initiation	HIV positive test: Days after PrEP initiation
Stopped on Day 6 because of side effects	Day 61
No known PrEP stop	Day 316
Stopped on Day 127 because of side effects	Day 150
No known PrEP stop	Day 303
Stopped on Day 1 because of side effects	Day 379

PrEP, pre-exposure prophylaxis.